Systems Pharmacology Reveals Type I Interferon and Myeloid-Like B Cell Reprogramming as Druggable Axes in Antiphospholipid Syndrome

Antiphospholipid syndrome (APS) lacks targeted therapies beyond anticoagulation, and its molecular heterogeneity remains poorly characterized. We employed an integrative systems pharmacology approach combining weighted gene co-expression network analysis (WGCNA), single-cell RNA sequencing, Connectivity Map (CMap) screening, and molecular docking to identify druggable targets in APS. WGCNA of bulk RNA-seq data from neutrophils (n = 18) and whole blood (n = 88) identified two disease-associated modules: ME10 (176 genes, r = 0.77, interferon-I signaling) and ME2 (3409 genes, r = 0.79, degranulation/innate activation). Single-cell analysis of 26,936 B cells revealed transitional B cells with elevated ME2 scores and aberrant SPI1 expression, suggesting myeloid-like transcriptional reprogramming. CMap analysis ranked chloroquine, a first-line APS therapy, among top ME2 candidates (NCS = −2.07), validating the computational approach. DrugBank mapping identified 14 FDA-approved drugs targeting module genes, and a 3-gene machine learning signature (CORO1A, ANKRD22, IFITM1) achieved cross-tissue validation AUC of 0.802. External validation confirmed ME2 pathway modulation by NAPc2 intervention and cross-tissue module conservation in platelets. Patient-level ME10 x ME2 stratification revealed four molecular subtypes with distinct pathway activation profiles. This framework nominates druggable targets across both IFN-I and degranulation pathways, providing a foundation for pathway-guided precision medicine in APS.